4.7 Article

Transcriptomics in Interferon-α-Treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression

Journal

NEUROPSYCHOPHARMACOLOGY
Volume 41, Issue 10, Pages 2502-2511

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2016.50

Keywords

-

Funding

  1. Johnson Johnson
  2. Medical Research Council (UK)
  3. Wellcome Trust
  4. Bristol-Myers Squibb
  5. Gilead
  6. Achillon
  7. AbbVie
  8. Astellas
  9. Boehringer Ingelheim
  10. Janssen
  11. Merck
  12. Roche
  13. BMS
  14. GSK
  15. Lundbeck
  16. Novartis
  17. Academy of Medical Sciences (AMS) [AMS-SGCL5-Mondelli] Funding Source: researchfish
  18. Medical Research Council [MR/N029488/1, MR/L014815/1, G108/603, MR/J002739/1] Funding Source: researchfish
  19. National Institute for Health Research [CL-2008-17-005, NF-SI-0515-10102] Funding Source: researchfish
  20. MRC [MR/L014815/1, G108/603, MR/N029488/1, MR/J002739/1] Funding Source: UKRI

Ask authors/readers for more resources

Owing to the unique opportunity to assess individuals before and after they develop depression within a short timeframe, interferon-alpha (IFN-a) treatment for chronic hepatitis C virus (HCV) infection is an ideal model to identify molecular mechanisms relevant to major depression, especially in the context of enhanced inflammation. Fifty-eight patients were assessed prospectively, at baseline and monthly over 24 weeks of IFN-alpha treatment. New-onset cases of depression were determined using the Mini International Neuropsychiatric Interview (MINI). Whole-blood transcriptomic analyses were conducted to investigate the following: (I) baseline gene expression differences associated with future development of IFN-alpha-induced depression, before IFN-alpha, and (2) longitudinal gene expression changes from baseline to weeks 4 or 24 of IFN-alpha treatment, separately in those who did and did not develop depression. Transcriptomics data were analyzed using Partek Genomics Suite (I.4-fold, FDR adjusted p <= 0.05) and Ingenuity Pathway Analysis Software. Twenty patients (34%) developed 1FN-alpha-induced depression. At baseline, 73 genes were differentially expressed in patients who later developed depression compared with those who did not. After 4 weeks of IFN-a treatment, 592 genes were modulated in the whole sample, representing primarily IFN-alpha-responsive genes. Substantially more genes were modulated only in patients who developed depression (n = 506, compared with n = 70 in patients who did not), with enrichment in inflammation-, neuroplasticity- and oxidative stress-related pathways. A similar picture was observed at week 24. Our data indicate that patients who develop IFN-alpha-induced depression have an increased biological sensitivity to IFN-alpha, as shown by larger gene expression changes, and specific signatures both as predictors and as correlates.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available